Pulse Biosciences ^{Priced, Nasdaq: PLSE}

We are a development-stage medical device company using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling or NPES. NPES is a local and drug-free technology that utilizes ultra-short, nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. We believe that NPES can induce a variety of cellular responses including secretion, apoptosis and necrosis by modulating the NPES pulses, making it applicable to a wide variety of cell types and therapeutic applications. One of the more promising applications of NPES is the treatment of solid tumors, where pre-clinical data developed by Pulse Biosciences and others have shown that NPES provides effective local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the treated cells. We believe we will establish NPES as a new treatment modality across a variety of applications, including both veterinary and human oncology, dermatology, aesthetics and other minimally invasive applications where current ablation modalities do not provide the benefits of NPES.